|  | 
|  |  | 
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. | 
|   
 
    
    
    
Hype and overvaluation are common in biotech stocks. Some famous ones are the sepsis wars between XOMA, SYGN (Synergen) and Centocor (CNTO) and Immune Response's (IMNR) slide from $70 to below $5. More recently, look at the charts for CARN ($50 to $6) and NRLD ($20 to $5) in the space of a few months. Maybe some of you don't realize, but there is great opportunity here. Shorting is easy, can be profitable, and provides a hedge against market correction. Since most of the discussions on this forum tend to be back-slapping, bullish, self-congratulatory conversations about how well we pick stocks as they are going up, I thought a more cynical (and perhaps more reasoned) discussion about the biotechs/medical stocks could be of use (and point me to more short ideas). Soon, I will post a brief discussion on how to short for those of you aren't aware of how to do it. It will be followed by a few of my favorite shorts (past and present). Good hunting, Kafka666 | ||||||||||||||
| 
 
 | 
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings | 
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI | 
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |